PEOPLE - Bausch & Lomb announces the following appointments:
This article was originally published in Clinica
Following an organisational restructure, Bausch & Lomb (Rochester, New York) has announced the following appointments. Theresa Shappell, previously CEO and co-founder of Excalibur Technologies, has been appointed to the newly created position of vice-president of US commercial operations. Donald Mooney, who has served B&L since 1999, has been appointed vice-president of marketing for the Americas Region. Efrain Rivera, the current president of B&L in Latin America, will assume additional marketing and sales responsibilities in Canada. Further appointments are pending.
You may also be interested in...
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.
It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations – and in patient treatment pathways.